Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck Patent GmbH | 1,513 |
| 2 | Merck Sharp & Dohme LLC | 711 |
| 3 | Celgene Corp | 477 |
| 4 | Merck and Co Inc | 310 |
| 5 | Immunomedics Inc | 276 |
| 6 | Pharmamar SA | 275 |
| 7 | Pfizer Inc | 245 |
| 8 | Gilead Sciences Inc | 188 |
| 9 | Pfizer Corp SRL | 184 |
| 10 | Pharmacyclics LLC | 160 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 11,219 |
| 2 | A61K | Medicinal preparations | 9,251 |
| 3 | C07D | Heterocyclic compounds | 6,767 |
| 4 | C07K | Peptides | 2,751 |
| 5 | C12N | Microorganisms, enzymes | 915 |
| 6 | Y02A | Climate change adaptation | 874 |
| 7 | G01N | Investigating / analysing materials | 722 |
| 8 | C07C | Acyclic and carbocyclic compounds | 664 |
| 9 | C07B | General methods of organic chemistry | 482 |
| 10 | C07F | Organometallic compounds | 463 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| APLIDINE FOR MULTIPLE MYELOMA TREATMENT | 2004 | Dana Farber Cancer Institute Inc | 13 |
| Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | 2008 | Pharmamar SA | 12 |
| Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | 2010 | Pharmamar SA | 8 |
| TREATMENT OF CANCERS BY APLIDINE IN CONJUNCTION WITH A MYOPROTECTOR | 2003 | Pharmamar SA | 4 |
| SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | 2003 | Pharmamar SA | 4 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Cancer therapeutics and mechanisms | 1 |
| 2 | Melanoma and MAPK Pathways | 1 |
| 3 | Synthesis and Biological Activity | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | José Jimeno | PharmaMar (Spain) | 27 |
| 2 | Glynn Faircloth | PharmaMar (Spain) | 12 |
| 3 | José A. López-Martín | PharmaMar (Spain) | 12 |
| 4 | Alejandro Losada | PharmaMar (Spain) | 10 |
| 5 | Pablo Avilés | PharmaMar (Spain) | 10 |
| 6 | Alberto Múñoz | Universidad Autónoma de Madrid | 9 |
| 7 | Jos H. Beijnen | Utrecht University | 7 |
| 8 | Maurizio D’Incalci | Mario Negri Institute for Pharmacological Research | 7 |
| 9 | Carlos M. Galmarini | PharmaMar (Spain) | 5 |
| 10 | Carmen Cuevas | PharmaMar (Spain) | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A | 2021 | 365 | SARS-CoV-2 and COVID-19 Research |
| Cytoskeleton-mediated Death Receptor and Ligand Concentration in Lipid Rafts Forms Apoptosis-promoting Clusters in Cancer Chemotherapy | 2005 | 183 | Protein Kinase Regulation and GTPase Signaling |
| AplidinTM Induces Apoptosis in Human Cancer Cells via Glutathione Depletion and Sustained Activation of the Epidermal Growth Factor Receptor, Src, JNK, and p38 MAPK | 2002 | 156 | Synthesis and biological activity |
| Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4 | 2003 | 145 | Angiogenesis and VEGF in Cancer |
| Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates | 1996 | 140 | Chemical Synthesis and Analysis |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Plitidepsin?
Which organizations hold the most patents related to Plitidepsin?
What are the main research topics associated with Plitidepsin publications?
Who are the most prolific authors publishing on Plitidepsin?
What patent classifications are most relevant to Plitidepsin intellectual property?